Biomind Labs CEO Alejandro Antalich tells Proactive the Toronto, Canada-based group was recently granted approval by the Brazilian Institutional Review Board to begin its Phase II clinical study evaluating its formulation of DMT for treatment-resistant depression.
Antalich says the group is recruiting patients for the study, and is hopeful it would be able to submit an IND to the US FDA by next year.